Live Breaking News & Updates on Central Dr

Stay updated with breaking news from Central dr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Reddy's to make, sell Eli Lilly's COVID-19 drug Baricitinib in India; 5th drugmaker to do so


Story
Dr Reddy s to make, sell Eli Lilly s COVID-19 drug Baricitinib in India; 5th drugmaker to do so
Dr Reddy s has also tied up with Russian Direct Investment Fund, Russia s sovereign wealth fund that has bankrolled Sputnik V. It has also collaborated with DRDO to develop an anti-Covid drug, 2-deoxy-D-glucose (2-DG), which has also received approval from DCGI
BusinessToday.In | May 12, 2021 | Updated 11:31 IST
Baricitinib has received restricted emergency use approval from the health ministry s central drugs standard control organisation
Dr Reddy s Laboratories has entered into a royalty-free, non-exclusive voluntary licencing agreement with US-based pharma major Eli Lilly and Company for the manufacture and sale of the drug, Baricitinib. Baricitinib has received restricted emergency use approval from the health ministry s central drugs standard control organisation for use in combination with Remdesivir for treatment of suspected or confirmed COVID-19 p ....

Andhra Pradesh , Eli Lilly , Deepak Sapra , National Stock Exchange On , Institute Of Nuclear Medicine , Development Organisation , Defence Research , Russian Direct Investment Fund , Chief Executive Officer , Sun Pharmaceutical , Drugs Controller General , Nuclear Medicine , Allied Sciences , Molecular Biology , National Stock Exchange , Dr Reddys To Make Baricitinib , Dr Reddys Get Baricitinib Licence , Baricitinib Manufacturing In India , Cipla Ties Up With Eli Lilly , Covid 19 Treatment In India , Baricitinib For Covid 19 , Natco Pharma , Emergency Use Approval , Baricitinib Tablets , Central Dr , ஆந்திரா பிரதேஷ் ,